A new cut point for Unfavorable Intermediate and High-Risk patients

The GPS assay stratifies unfavorable intermediate and high-risk patients into two distinct groups with highly differing long-term outcomes1-2


Unfavorable Intermediate-Risk and High-Risk Patients


GPS 40 wedge

orange person

May be candidates for less aggressive treatment

grey person

May be candidates for more aggressive treatment

THE ONCOTYPE DX GPS TEST FOR UNFAVORABLE INTERMEDIATE AND HIGH-RISK PROSTATE CANCER

See how men with unfavorable intermediate and high-risk prostate cancer can be stratified into two distinct groups with highly differing long-term outcomes. Use the GPS assay to make informed treatment decisions based on a patient's genomic risk.

Additional Resources

REFERENCES

  1. Cullen et al. Urology. 2020.
  2. Data on file.
Making cancer care smarter.®